Surveillance Until Rituximab Retreatment Does Not Increase Anxiety in Non-Hodgkin Lymphoma

Findings suggest the relapse is not a cause for increased anxiety as long as the recurrence is quickly addressed with well tolerated therapy like a single dose of rituximab. Therefore, rituximab retreatment can be used in place of rituximab maintenance as it can save resources while achieving comparable clinical and patient-centered outcomes.